PHAR Pharming Group NV: Price-to-Projected Revenue Ratio
Pharming Group N.V. creates a unique environment for the therapy of rare immune pathologies, offering irreplaceable solutions for hereditary angioedema. The forward P/S history visualizes the business valuation trend, where the current metric equals 2.20. High margins are sustained by the absence of biosimilars, while R&D costs are offset by high-value sales of Ruconest, produced using transgenic rabbits.
Comprehensive metric breakdowns and analytics for Pharming Corp (PHAR)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
- financial results and valuation multiples details:
PHAR - Annual Net Income|Future Profit Pharming Group N.V.|PHAR - Company Value to Net Income|Forward P/E Multiple Pharming|PHAR - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Corp|PHAR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Pharming Group|PHAR - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pharming.com|PHAR - Earnings growth in current year|Net earnings per share growth forecast for next year Pharming Group N.V.
- company sales and revenue statistics:
Analysis of all company metrics:Pharming Group PHAR
Forward P/S determines the fair acquisition value of a business through the ratio of current market capitalization to projected revenue. By analyzing the forward P/S of a company, an investor assesses the market's willingness to pay a premium for future cash flows. This metric measures the efficiency of asset monetization while excluding short-term volatility. For Pharming Group N.V. (PHAR), stable pricing for orphan drugs minimizes the risk of dumping, making this multiple a reliable indicator of fundamental value.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Future Price to Revenue ADMA|PTGX: Forward P/S Multiple|immunovant.com - Forward Price to Sales|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX - Forward Price-to-Revenue Multiple|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ABCL|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|PGEN - Projected Price to Revenue|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Forward Price to Sales|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Projected Price to Revenue Immunome Bio|GOSS - Price-to-Projected Revenue Ratio|Forward Price to Sales KALV (kalvista.com)|Septerna (SEPN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pieris Pharma (PVLA)|Forward Price-to-Revenue Multiple SVRA|Forward P/S Multiple Rigel Corp|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Future Price to Revenue|enGene - Forward Price-to-Revenue Multiple|Forward Price to Sales RAPT|JBIO - Price-to-Projected Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Projected Revenue|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|TLSA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CABA|Price-to-Projected Revenue Ratio VTYX|Forward Price-to-Revenue Multiple THTX (Theratechnologies Inc)|Market Cap to Expected Sales Ratio Avalo Therapeutics Inc|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Future Price to Revenue|Climb Bio - Forward P/S Multiple|Forward Price to Sales ZURA (Zura Bio Ltd)|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ImageneBio|STTK: Forward Price to Sales|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|CNTB: Future Price to Revenue|Forward P/S Multiple IMUX (Immunic)|Forward Price to Sales ATRA|InflaRx GmbH - Forward P/S Multiple|XFOR - Forward P/S Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Celularity - Forward Price to Sales|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Forward P/S Multiple KZR|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward Price-to-Revenue Multiple BOLT (Bolt Biotherapeutics)|Forward P/S Multiple hcwbiologics.com (HCWB)|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Projected Revenue|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue HIND (Vyome Therapeutics)|REVB (Revelation Biosciences) - Forward P/S Multiple|INDP: Forward Price to Sales|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Forward Price to Sales ALLK|HOOK - Price-to-Projected Revenue Ratio|IGM Biosciences, Inc. (IGMS) - Forward Price-to-Revenue Multiple|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Market Cap to Projected Revenue THRD (Third Harmonic Bio Inc)
